$MRK News Article - Pivotal RESTORE-IMI 2 Phase 3 Study of Merck's RECARBRIO(TM) (imipenem, cilastatin, and relebactam) in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Met Primary Endpoint
https://marketwirenews.com/news-releases/pivo...45471.html